- $78.57m
- $73.77m
- $130.69m
- 84
- 69
- 66
- 85
Annual income statement for inTest, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 53.8 | 84.9 | 117 | 123 | 131 |
Cost of Revenue | |||||
Gross Profit | 24.1 | 41.2 | 53.4 | 57 | 55.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 55 | 76.4 | 106 | 113 | 127 |
Operating Profit | -1.22 | 8.46 | 10.7 | 10.4 | 3.39 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.23 | 8.4 | 10.1 | 11 | 3.45 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.895 | 7.28 | 8.46 | 9.34 | 2.89 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.895 | 7.28 | 8.46 | 9.34 | 2.89 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.895 | 7.28 | 8.46 | 9.34 | 2.89 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.011 | 0.685 | 0.838 | 0.832 | 0.284 |